HONG KONG, CHINA--(Marketwired - November 01, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)
Director's Share Dealing
London: Tuesday, November 1, 2016: Hutchison China MediTech Limited ("Chi-Med") (NASDAQ: HCM) (AIM: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the "Ordinary Shares") at an average price of GBP18.453305 per share between October 24, 2016 and October 28, 2016 under a personal share trading plan (the "Plan"). Pursuant to the Plan, a total of 20,000 Ordinary Shares will be sold between October 24, 2016 and November 23, 2016 (inclusive). The Plan (and the previous sale of 15,000 Ordinary Shares made by Mr Howell on October 7, 2016) has been put in place to facilitate financial settlement arising from a marital separation agreement.
Following the above sale of 10,000 Ordinary Shares, the holding of Mr Howell is 128,600 Ordinary Shares, representing approximately 0.21% of the current issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Mr Michael Howell
2 Reason for the notification
a) Position/status Independent Non-executive Director of Chi-
Med
b) Initial Initial notification
notification/Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hutchison China MediTech Limited
b) LEI N/A
4 Details of the transaction(s): section to be repeated for (i) each type
of instrument; (ii) each type of transaction; (iii) each date; and (iv)
each place where transactions have been conducted
a) Description of the financial Ordinary Shares of US$1.00 each
instrument, type of DI ISIN: KYG4672N1016
instrument ADS ISIN: US44842L1035
Identification code
b) Nature of the transaction Sale of 10,000 Ordinary Shares between
October 24, 2016 and October 28, 2016 at an
average price of GBP18.453305
Price(s) Volume(s)
GBP18.25 339
GBP18.30 2,661
GBP18.40 1,000
GBP18.50 3,500
GBP18.60 2,500
d) Aggregated information Aggregated volume: 10,000
Price information: GBP18.453305
- Aggregated volume
- Price
e) Date of the transaction 2016-10-24; 14:07 - disposal of 339
Ordinary Shares
2016-10-25; 14:05 - disposal of 661
Ordinary Shares
2016-10-25; 14:44 - disposal of 2,000
Ordinary Shares
2016-10-25; 15:29 - disposal of 1,000
Ordinary Shares
2016-10-26; 13:57 - disposal of 3,000
Ordinary Shares
2016-10-28; 12:48 - disposal of 2,500
Ordinary Shares
2016-10-28; 14:09 - disposal of 500
Ordinary Shares
f) Place of the transaction London Stock Exchange (XLON)
NOTES TO EDITORS
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media
Enquiries
Anthony Carlisle, +44 7973 611 888 anthony.carlisle@cdrconsultancy.co.uk
Citigate Dewe (Mobile)
Rogerson
U.S. Based Media
Enquiries
Brad Miles, BMC +1 (917) 570 7340 bmiles@bmccommunications.com
Communications (Mobile)
Susan Duffy, BMC +1 (917) 499 8887 sduffy@bmccommunications.com
Communications (Mobile)
Investor Relations
Matt Beck, The Trout +1 (917) 415 1750 mbeck@troutgroup.com
Group (Mobile)
David Dible, +44 7967 566 919 david.dible@citigatedr.co.uk
Citigate Dewe (Mobile)
Rogerson
Panmure Gordon (UK)
Limited
Richard Gray / +44 (20) 7886 2500
Andrew Potts
